610 related articles for article (PubMed ID: 12393465)
21. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression.
Yeh JR; Munson KM; Chao YL; Peterson QP; Macrae CA; Peterson RT
Development; 2008 Jan; 135(2):401-10. PubMed ID: 18156164
[TBL] [Abstract][Full Text] [Related]
22. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
Kwong YL; Chan V; Wong KF; Chan TK
Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132
[TBL] [Abstract][Full Text] [Related]
23. Pontin is a critical regulator for AML1-ETO-induced leukemia.
Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
[TBL] [Abstract][Full Text] [Related]
24. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
[TBL] [Abstract][Full Text] [Related]
25. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
[TBL] [Abstract][Full Text] [Related]
26. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
[TBL] [Abstract][Full Text] [Related]
28. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
[TBL] [Abstract][Full Text] [Related]
29. The ETO domain is necessary for the developmental abnormalities associated with AML1-ETO expression in the hematopoietic stem cell compartment in vivo.
de Guzman CG; Johnson A; Klug CA
Blood Cells Mol Dis; 2003; 30(2):201-6. PubMed ID: 12732184
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.
de Guzman CG; Warren AJ; Zhang Z; Gartland L; Erickson P; Drabkin H; Hiebert SW; Klug CA
Mol Cell Biol; 2002 Aug; 22(15):5506-17. PubMed ID: 12101243
[TBL] [Abstract][Full Text] [Related]
31. AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.
Choi Y; Elagib KE; Goldfarb AN
Crit Rev Eukaryot Gene Expr; 2005; 15(3):207-16. PubMed ID: 16390317
[TBL] [Abstract][Full Text] [Related]
32. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
Martens JH; Mandoli A; Simmer F; Wierenga BJ; Saeed S; Singh AA; Altucci L; Vellenga E; Stunnenberg HG
Blood; 2012 Nov; 120(19):4038-48. PubMed ID: 22983443
[TBL] [Abstract][Full Text] [Related]
33. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
34. AML1-ETO inhibits acute myeloid leukemia immune escape by CD48.
Wang Z; Guan W; Wang M; Chen J; Zhang L; Xiao Y; Wang L; Li Y; Yu L
Leuk Lymphoma; 2021 Apr; 62(4):937-943. PubMed ID: 33225787
[TBL] [Abstract][Full Text] [Related]
35. Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.
Duque-Afonso J; Solari L; Essig A; Berg T; Pahl HL; Lübbert M
Br J Haematol; 2011 Jun; 153(5):612-22. PubMed ID: 21488857
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
[TBL] [Abstract][Full Text] [Related]
37. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
Kozu T; Miyoshi H; Shimizu K; Maseki N; Kaneko Y; Asou H; Kamada N; Ohki M
Blood; 1993 Aug; 82(4):1270-6. PubMed ID: 8353289
[TBL] [Abstract][Full Text] [Related]
38. Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.
Shimada H; Ichikawa H; Ohki M
Leukemia; 2002 May; 16(5):874-85. PubMed ID: 11986950
[TBL] [Abstract][Full Text] [Related]
39. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
40. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
